Modulatory effect of bucillamine (SA96) on interleukin-1-and/or -2-induced proliferation of T lymphocytes.
Bucillamine [SA96:N-(2-mercapto-2-methylpropanoyl)-L-cysteine], a synthetic SH compound, has recently been developed as remission-inducing agent for rheumatoid arthritis (RA), and its clinical usefulness for RA has been proved in Japan. Bucillamine suppressed the mitogen-induced proliferation of murine lymphocytes in vitro. The present study was undertaken to clarify the effect of bucillamine primarily on the release of interleukin (IL)-1 from monocytes and on the proliferation of T cells. Bucillamine significantly inhibited IL-1-induced thymocyte proliferation in a dose-dependent manner. And, bucillamine also inhibited IL-2-induced proliferation at the concentration of 1 x 10(-4) M, but augmented proliferation at the concentration of 1 x 10(-5) M. In contrast, D-penicillamine (an analogous SH compound to bucillamine) did not show any significant effect at similar concentrations.
Sasano
M
M
Institute of Rheumatology, Tokyo Women's Medical College, Japan.
Goto
M
M
Nishioka
K
K
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D002455:Cell Division; D003545:Cysteine / Q000031:analogs & derivatives* / Q000494:pharmacology; D006801:Humans; D007375:Interleukin-1 / Q000097:blood / Q000494:pharmacology*; D007376:Interleukin-2 / Q000494:pharmacology*; D010835:Phytohemagglutinins / Q000494:pharmacology; D013601:T-Lymphocytes / Q000166:cytology*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007375:Interleukin-1; D007376:Interleukin-2; D010835:Phytohemagglutinins; D003545:Cysteine; C026535:bucillamine